The inflammatory bowel disease biologics market is projected to grow from USD 63.9 billion in 2026 to USD 149.9 billion by 2036, at a CAGR of 8.9%. Anti-TNF agents will dominate with a 38.0% market share, while crohn’s disease will lead the applications segment with a 54.0% share.